- ISIN CH0325814116
- Country Schweiz
Kuros Biosciences AG
Annual General Meeting of Kuros Biosciences approves all resolutions
|
Kuros Biosciences AG / Key word(s): AGMEGM Schlieren (Zurich), Switzerland, June 8, 2022 – Kuros Biosciences (SIX:KURN) today announced that its Annual General Meeting approved all resolutions proposed by the Board of Directors.
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and Consolidated Financial Statements for the year 2021 and took note of the Reports of the Auditors. Shareholders granted discharge to the Board and the persons entrusted with the Management, voted in favor of the proposed appropriation of the Annual Results and approved the compensation for the members of the Board of Directors and the Executive Committee. Clemens van Blitterswijk was re-elected as Chairman and Leanna Caron, Joost de Bruijn, Scott P. Bruder, Oliver Walker and Chris Fair were re-elected as members of the Board. Leanna Caron, Chris Fair and Oliver Walker were re-elected as members of the Compensation Committee. The law firm Keller KLG, Zurich was re-elected as independent Proxy. PricewaterhouseCoopers were confirmed for another one-year term as the Company’s auditor.
The Annual General Meeting further approved with the required 2/3 majority the adjustment to the articles of association regarding
The Annual General Meeting took place at the Company’s headquarters in Schlieren without the physical presence of the shareholders and only voting through the independent proxy was permitted. 15,518,179 shares or 47.3% of a total of 32,811,378 shares were represented. For further information, please contact:
About Kuros Biosciences AG Kuros Biosciences is a fast-growing leader in the development of spinal fusion biologics that ease the burden of back pain. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. The company’s first commercial product, MagnetOs, is a unique synthetic bone graft that has already been used successfully across three continents and in some 4,000 spinal fusion surgeries. The next candidate in the Kuros pipeline is Fibrin-PTH – the first drug-biologic combination for interbody spinal fusions, currently undergoing a Phase 2 clinical trial in the US. For more information on the company, its products and pipeline, visit kurosbio.com.
Forward Looking Statements This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments. End of ad hoc announcement |
| Language: | English |
| Company: | Kuros Biosciences AG |
| Wagistrasse 25 | |
| 8952 Schlieren | |
| Switzerland | |
| Phone: | +41 44 733 4747 |
| Fax: | +41 44 733 4740 |
| E-mail: | info@kurosbio.com |
| Internet: | www.kurosbio.com |
| ISIN: | CH0325814116 |
| Valor: | 32581411 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1371445 |
| End of Announcement | EQS News Service |